Jan 10 (Reuters) - Tiziana Life Sciences Ltd TLSA.O:
TIZIANA ANNOUNCES REDUCTION OF SIDE EFFECTS COMMONLY SEEN WITH DISCONTINUATION OF GLP-1 AGONISTS WITH NASAL ANTI-CD3
TIZIANA LIFE SCIENCES LTD - GLP-1 DRUGS FACE LONG TERM TOLERABILITY ISSUES
TIZIANA LIFE SCIENCES LTD - FDA ALLOWS ADDITIONAL 20 PATIENTS IN FORALUMAB EXPANDED ACCESS PROGRAM
Source text: nGNX1JJ8Xz
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.